To achieve this, Qian and co‐workers designed an easy‐operating procedure to fabricate a therapeutics‐based nanosystem for cancer immunotherapy.[143] The developed nanomedicine with a Lyp‐1 sequence could be degraded by overexpressed MMP‐2 in the TME, leading to enhanced tumor penetration and active tumor targeting. Here, PTPN22 is linked to neoplasm.